Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 39 No. 1 › Efficacy of Olanzapine...
DRUG DISPOSITION AND PHARMACOKINETICS

Efficacy of Olanzapine and Risperidone in Schizophrenia: A Randomized Double-Blind Crossover Design

Jose M. Canive, MD, Gregory A. Miller, PhD, Jessica G. Irwin, BS, Sandra N. Moses, PhD, Robert J. Thoma, PhD, J. Christopher Edgar, PhD, Andrea Sherwood, PhD, Fernando Torres, MD, Marianna LaNoue, PhD, Stephen Lewis, MD, Faith M. Hanlon, PhD, Michael P. Weisend, PhD, Valerie Mead, MD, and Vicente B. Tuason, MD
Psychopharmacology Bulletin 39(1): 105-116, 2006/09/21; https://doi.org/10.64719/pb.4157

Abstract

This article compares the efficacy of olanzapine and risperidone for positive and negative symptoms using an 18-week, randomized, double-blind, crossover design. The hypotheses were that olanzapine would be more efficacious for treating negative symptoms, and that risperidone would be superior in treating positive symptoms. Positive and negative symptom scores improved throughout treatment, regardless of medication type. Differences between the medications were found for negative and general psychopathology rating scales. Overall, olanzapine led to greater improvements in negative symptoms than did risperidone.

Keywords

crossover design, efficacy, olanzapine, risperidone

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In
Not yet subscribed? View subscription options

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Jose M. Canive, MD, Gregory A. Miller, PhD, Jessica G. Irwin, BS, Sandra N. Moses, PhD, Robert J. Thoma, PhD, J. Christopher Edgar, PhD, Andrea Sherwood, PhD, Fernando Torres, MD, Marianna LaNoue, PhD, Stephen Lewis, MD, Faith M. Hanlon, PhD, Michael P. Weisend, PhD, Valerie Mead, MD, and Vicente B. Tuason, MD. Efficacy of Olanzapine and Risperidone in Schizophrenia: A Randomized Double-Blind Crossover Design. Psychopharmacology Bulletin. 2006/09/21; 39(1):105-116. https://doi.org/10.64719/pb.4157